Key drugs facing patent cliffs during this period include Keytruda (pembrolizumab) starting around 2028, Eliquis (apixaban) starting around 2026 to 2028 depending on PTE outcomes, Opdivo (nivolumab) starting around 2026, Xarelto (rivaroxaban) with varying international timelines, Jardiance (empagliflozin) with U.S
Plasma levels of acylcarnitine in newborn infants can be detected in a small blood sample by tandem mass spectrometry
The blend is a compounded formulation, not an FDA-approved product
Resistance training preserves muscle mass (protecting your metabolic rate), and daily movement (walking 7,000 to 10,000 steps) helps maintain your calorie deficit even if your intake edges up slightly
The nonenzymatic alternative pathway, such as polyamine (PA) breakdown for GABA synthesis, also exists, particularly under oxidative stress